Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7812292 | 0.92 | CYP1A2 (0.46) | CYP1A2NOTUMTSHRKDM4ENPC1 | |
| SCHEMBL769959 | 0.81 | ALDH1A1 (0.45) | CYP1A2NOTUMALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL769634 | 0.81 | ALDH1A1 (0.45) | CYP1A2NOTUMALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL25097 | 0.81 | ALDH1A1 (0.45) | CYP1A2NOTUMALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL8590691 | 0.81 | CYP2A6 (0.50) | CYP1A2KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL183516 | 0.80 | ALDH1A1 (0.35) | RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL41140 | 0.80 | ALDH1A1 (0.42) | CYP1A2NOTUMNPC1RAB9AALDH1A1 | |
| SCHEMBL38202 | 0.80 | ALDH1A1 (0.42) | CYP1A2NOTUMNPC1RAB9AALDH1A1 | |
| SCHEMBL7180814 | 0.80 | TSHR (0.35) | CYP1A2TSHRSMN1; SMN2 | |
| SCHEMBL8588843 | 0.79 | CYP2A6 (0.48) | CYP1A2KDM4ENPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116891466-A | Pyrazole-containing dithiazole carboxamide derivative and preparation method and application thereof | 南开大学 | 2023-10-17 | — | — | CN | claimed |
| WO-2018136792-A1 | INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-26 | — | — | WO | claimed |
| CN-104114169-A | Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis | ATOPIX THERAPEUTICS LTD | 2014-10-22 | — | — | CN | claimed |
| EP-2513064-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-10-24 | — | — | EP | claimed |
| CN-102264734-A | Alkaloid aminoester derivatives and medicinal composition thereof | — | 2011-11-30 | — | — | CN | claimed |
| WO-2011080132-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2011-07-07 | — | — | WO | claimed |
| US-7923465-B2 | CB2 agonists; pain, neurodegenative disorders, eating disorders, weight loss or control, obesity, dyslipidemia, drug abuse, vision defect, neurodegenerative diseases; 5-(2,4-difluorophenyl)-4,5-diazatricyclo[5.2.1.0.sup.2,6.]deca-2-(6),3-dien-3-yl-phenylmethanone; antiinflammatory agent, antidepressant | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-04-12 | — | — | US | claimed |
| EP-1902034-B1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS SA (CH) | 2011-03-30 | — | — | EP | claimed |
| EP-1978967-B1 | QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | claimed |
| US-20080234259-A1 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-09-25 | — | — | US | claimed |
| US-6610871-B1 | Reacting with an organozinc compound; chemoselective for Sn2' substitution and/or stereoselective. | AVECIA LIMITED (GB) | 2003-08-26 | — | — | US | claimed |
| WO-2003022842-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-20 | — | — | WO | claimed |
| EP-0895988-B1 | Arylsulfonylamino hydroxamic acid derivatives | PFIZER PROD INC (US) | 2002-05-22 | — | — | EP | claimed |
| EP-1173405-A4 | SYNTHESIS OF N4, N4' -DIPHENYL-N4, N4' -DI-M-TOLYL-BIPHENYL-4,4'-DIAMINE FROM AN UNSYMMETRICAL AMINE | BOULDER SCIENT CO (US) | 2002-04-17 | — | — | EP | claimed |
| EP-1173405-A1 | SYNTHESIS OF N4, N4' -DIPHENYL-N4, N4' -DI-M-TOLYL-BIPHENYL-4,4'-DIAMINE FROM AN UNSYMMETRICAL AMINE | BOULDER SCIENTIFIC COMPANY (US) | 2002-01-23 | — | — | EP | claimed |
| WO-2001055087-A1 | SYNTHESIS OF N4, N4'-DIPHENYL-N4, N4'-DI-M-TOLYL-BIPHENYL-4,4'-DIAMINE FROM AN UNSYMMETRICAL AMINE | BOULDER SCIENTIFIC COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| US-6107337-A | ANTIARTHRITIC AGENTS; ANTICARCINOGENIC AGENTS | PFIZER INC. (US) | 2000-08-22 | — | — | US | claimed |
| EP-0895988-A1 | Arylsulfonylamino hydroxamic acid derivatives | Pfizer Products Inc. (US) | 1999-02-10 | — | — | EP | claimed |
| EP-0414299-B1 | Biocidal azoxime compounds | SHELL INT RESEARCH (NL) | 1994-06-15 | — | — | EP | claimed |
| EP-0101023-A1 | Process for preparing 2-carbamoyloxyalkyl-1,4-dihydropyridine derivatives and intermediates useful for the process | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1984-02-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234259-A1 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation | CNR2, CNR1, OPRL1 | CYP1A2 3079/4885NOTUM 2282/4885TSHR 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.